Clinical Trial

FXS6837 for the Treatment for IgAN Patients（Longterm Study）

Name: FXS6837 for the Treatment for IgAN Patients（Longterm Study） — clinical trial record (NCT07750665)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Not Yet Recruiting Phase 2

View on ClinicalTrials.gov →

Summary

This is a multicenter, open-label study to evaluate the long-term safety and efficacy of FXS6837 capsules in primary IgAN patients. About 60 IgAN patients who had received and completed FXS6837-IIb-201 study treatment will be enrolled to take FXS6837 capsules orally according to protocol for 2 years.

Trial Details

NCT Number	NCT07750665
Lead Sponsor	Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.
Conditions	Primary IgAN
Enrollment	60 participants
Start Date	2026-09-30
Primary Completion	2029-11-13 (estimated)
Study Completion	2030-01-04 (estimated)
Updated on ClinicalTrials.gov	2026-08-06